XML 41 R22.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

SHARE-BASED COMPENSATION | 12 Months Ended
--- | ---
Dec. 31, 2023
SHARE-BASED COMPENSATION [Abstract] |
SHARE-BASED COMPENSATION |
14. | SHARE-BASED COMPENSATION
With effect on January 1, 2024, the maximum number of shares which may be issued pursuant to all awards under its 2009 share incentive plan (the “Plan”) increased to 210,888,606 Class A ordinary shares. The Company amended the Plan in April 2022 to automatically increase on January 1 of each of 2023, 2024, 2025 and 2026 by 3% of the total number of ordinary shares of all classes of the Company outstanding on that day immediately before the increase. Under the Plan, the Company may grant options, restricted share award (“RSA”), restricted share unit (“RSU”) or share appreciation right (“SAR”) to its officers, employees, directors and other eligible persons (collectively known as “Eligible Persons”). The Plan is administered by an authorized administrator appointed by the Board of Directors of the Company set forth in the Plan (the “Plan Administrator”). All options granted have a contractual term of ten years. The options vest according to the stated vesting period in the grantee’s option agreement. The RSUs and SARs generally vest 25% on the first anniversary year from the stated vesting commencement date and the remaining 75% will vest in 12 substantially equal quarterly instalments. On April 17, 2022, 4,000,000 existing options were cancelled and 4,000,000 new options were granted concurrently to the same grantee with an exercise price of US$120 per share on the same date. The new options will vest every three months over a period of five years commencing April 30, 2022 and will expire 10 years after the grant date. This is accounted for as a modification and resulted in an incremental share-based compensation cost of US$99,198, which shall be recognised over the new vesting period of the new options of five years commencing April 30, 2022.
| (a) | Option granted to Eligible Persons
The following table summarizes the Company’s share option activity under the Plan:
|  | Number of options |  |  | Weighted average exercise price |  |  | Weighted average remaining contractual term |  |  | Aggregate intrinsic value |
|  |  |  |  | $ |  |  | Years |  |  | $ |
Outstanding, January 1, 2021 |  |  | 47,465,720 |  |  |  | 14.76 |  |  |  |  |  |  |  |
Granted |  |  | 4,162,121 |  |  |  | 269.09 |  |  |  |  |  |  |  |
Exercised |  |  | (5,405,228 | ) |  |  | 14.44 |  |  |  |  |  |  |  |
Forfeited |  |  | – |  |  |  |  |  |  |  |  |  |  |  |
Outstanding, December 31, 2021 |  |  | 46,222,613 |  |  |  | 37.70 |  |  |  | 6.89 |  |  |  | 8,822,987 |
Vested and expected to vest at December 31, 2021 |  |  | 46,222,613 |  |  |  | 37.70 |  |  |  |  |  |  |  |  |
Exercisable as of December 31, 2021 |  |  | 30,707,210 |  |  |  | 14.13 |  |  |  | 6.32 |  |  |  | 6,435,641 |
Outstanding, January 1, 2022 |  |  | 46,222,613 |  |  |  | 37.70 |  |  |  |  |  |  |  |  |
Granted |  |  | 30,000,000 |  |  |  | 120.00 |  |  |  |  |  |  |  |  |
Cancelled or forfeited |  |  | (4,012,516 | ) |  |  | 279.17 |  |  |  |  |  |  |  |  |
Exercised |  |  | (3,676,911 | ) |  |  | 13.82 |  |  |  |  |  |  |  |  |
Outstanding, December 31, 2022 |  |  | 68,533,186 |  |  |  | 60.87 |  |  |  | 7.30 |  |  |  | 1,433,420 |
Vested and expected to vest at December 31, 2022 |  |  | 68,533,186 |  |  |  | 60.87 |  |  |  |  |  |  |  |  |
Exercisable as of December 31, 2022 |  |  | 36,880,548 |  |  |  | 22.99 |  |  |  | 5.97 |  |  |  | 1,274,793 |
Outstanding, January 1, 2023 |  |  | 68,533,186 |  |  |  |  |  |  |  |  |  |  |  |  |
Granted |  |  | 1,925,000 |  |  |  | 60.00 |  |  |  |  |  |  |  |  |
Cancelled or forfeited |  |  | (9,292,295 | ) |  |  | 104.02 |  |  |  |  |  |  |  |  |
Exercised |  |  | (1,336,980 | ) |  |  | 7.19 |  |  |  |  |  |  |  |  |
Outstanding, December 31, 2023 |  |  | 59,828,911 |  |  |  | 55.34 |  |  |  | 6.18 |  |  |  | 944,611 |
Vested and expected to vest at December 31, 2023 |  |  | 59,828,911 |  |  |  | 55.34 |  |  |  |  |  |  |  |  |
Exercisable as of December 31, 2023 |  |  | 42,877,386 |  |  |  | 35.29 |  |  |  | 5.51 |  |  |  | 887,174 |
The aggregate intrinsic value is calculated to be the difference between the exercise price of the underlying awards and the fair value of the underlying stock at each reporting date, for those awards that have an exercise price below the estimated fair value of the Company’s ordinary shares. The Company calculated the estimated fair value of the options on the respective grant dates using the Black-Scholes Option Pricing Model with the following assumptions:
|  | Granted in 2021 |  | Granted in 2022 |  | Granted in 2023
Risk-free interest rates |  | 0.74% – 1.07% |  | 2.79% – 2.84% |  | 3.60% – 4.10%
Expected term |  | 5.6 – 7.5 years |  | 5.1 – 7.5 years |  | 6.5 – 7 years
Expected volatility |  | 32.1% – 33.0% |  | 48.7% – 55.9% |  | 60.2% – 62.0%
Expected dividend yield |  | – |  | – |  | –
The risk-free interest rate for periods within the contractual life of the option is based on the US Treasury Yields at the time of grant. The Company has used the simplified method to determine the expected term due to insufficient relevant historical exercise data to provide a reasonable basis to estimate expected term. The Company estimated expected volatility primarily based on the weighted-average historical share price volatility of the Company’s ADS. The Company’s management is ultimately responsible for the determination of the estimated fair value of its ordinary shares. The weighted-average grant-date fair value of share options granted during the years of December 31, 2021, 2022 and 2023 were $75.83, $57.74 and $40.62, respectively. The total fair value of share options vested during the years ended December 31, 2021, 2022 and 2023 was $88,507, $389,734 and $325,183, respectively. The aggregate intrinsic value of options exercised during the years ended December 31, 2021, 2022 and 2023 was $1,361,800, $143,176 and $72,072, respectively. As of December 31, 2023, there were $829,528 total unrecognized share-based compensation cost related to unvested options which is expected to be recognized over a weighted-average period of 3.31 years. Total unrecognized compensation cost may be adjusted for future changes in actual forfeitures.
| (b) | RSAs/RSUs granted to Eligible Persons
The following table summarizes the Company’s RSAs/RSUs activity under the Plan:
|  | Number of RSAs/RSUs |  |  | Weighted average grant date fair value |  |  | Weighted average remaining contractual life |  |  | Aggregate intrinsic value |
|  |  |  |  | $ |  |  | Years |  |  | $ |
Unvested, January 1, 2021 |  |  | 9,341,928 |  |  |  | 46.36 |  |  |  | 8.64 |  |  |  | 1,859,511 |
Granted |  |  | 3,551,491 |  |  |  | 258.97 |  |  |  |  |  |  |  |  |
Vested |  |  | (4,127,006 | ) |  |  | 40.59 |  |  |  |  |  |  |  |  |
Forfeited |  |  | (637,193 | ) |  |  | 102.92 |  |  |  |  |  |  |  |  |
Unvested, December 31, 2021 and January 1, 2022 |  |  | 8,129,220 |  |  |  | 137.76 |  |  |  | 8.47 |  |  |  | 1,818,588 |
Granted |  |  | 7,320,443 |  |  |  | 99.25 |  |  |  |  |  |  |  |  |
Vested |  |  | (3,864,257 | ) |  |  | 110.34 |  |  |  |  |  |  |  |  |
Forfeited |  |  | (1,933,175 | ) |  |  | 133.12 |  |  |  |  |  |  |  |  |
Unvested, December 31, 2022 and January 1, 2023 |  |  | 9,652,231 |  |  |  | 120.48 |  |  |  | 8.81 |  |  |  | 502,206 |
Granted |  |  | 7,119,505 |  |  |  | 63.46 |  |  |  |  |  |  |  |  |
Vested |  |  | (4,130,583 | ) |  |  | 109.11 |  |  |  |  |  |  |  |  |
Forfeited |  |  | (1,786,921 | ) |  |  | 116.01 |  |  |  |  |  |  |  |  |
Unvested, December 31, 2023 |  |  | 10,854,232 |  |  |  | 90.02 |  |  |  | 8.86 |  |  |  | 439,596 |
Share-based compensation cost for RSAs and RSUs is measured based on the fair value of the Company’s ordinary shares on the date of grant. The weighted-average grant-date fair value of RSAs and RSUs granted during the years ended December 31, 2021, 2022 and 2023 was $258.97, $99.25 and $63.46, respectively. The total fair value of RSAs and RSUs vested during the years ended December 31, 2021, 2022 and 2023 was $167,507, $426,398 and $450,703, respectively. As of December 31, 2023, there was $977,151 of unrecognized share-based compensation cost related to RSAs and RSUs which is expected to be recognized over a weighted-average vesting period of 2.55 years. Total unrecognized compensation may be adjusted for future changes in actual forfeitures.
| (c) | SARs granted to Eligible Persons
During the years ended December 31, 2022 and 2023, the Company granted 54,186 and 64,295 SARs, respectively, to the Eligible Persons. Fair value of the SARs is measured based on the fair value of the Company’s ordinary shares at the end of each reporting period. Total compensation expense relating to share options, RSAs, RSUs and SARs granted to employees after deducting forfeitures recognized for the years ended December 31, 2021, 2022 and 2023 is as follows:
|  | Year ended December 31, |
|  | 2021 |  |  | 2022 |  |  | 2023 |
|  | $ |  |  | $ |  |  | $ |
Share options: |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  |  | 390 |  |  |  | – |  |  |  | – |
Sales and marketing expenses |  |  | 5 |  |  |  | – |  |  |  | – |
General and administrative expenses |  |  | 207,204 |  |  |  | 313,917 |  |  |  | 253,408 |
Research and development expenses |  |  | 33 |  |  |  | 254 |  |  |  | 44 |
|  |  | 207,632 |  |  |  | 314,171 |  |  |  | 253,452 |
Cash received for the exercise in the respective years |  |  | 77,639 |  |  |  | 50,211 |  |  |  | 10,643 |
RSAs/ RSUs: |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  |  | 8,318 |  |  |  | 11,104 |  |  |  | 12,727 |
Sales and marketing expenses |  |  | 23,350 |  |  |  | 36,812 |  |  |  | 35,988 |
General and administrative expenses |  |  | 67,421 |  |  |  | 67,388 |  |  |  | 99,048 |
Research and development expenses |  |  | 148,592 |  |  |  | 283,747 |  |  |  | 282,381 |
|  |  | 247,681 |  |  |  | 399,051 |  |  |  | 430,144 |
SARs: |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  |  | 3,389 |  |  |  | (1,928 | ) |  |  | 383 |
Sales and marketing expenses |  |  | 6,850 |  |  |  | (1,762 | ) |  |  | 710 |
General and administrative expenses |  |  | 3,658 |  |  |  | (2,993 | ) |  |  | 200 |
Research and development expenses |  |  | 1,114 |  |  |  | (643 | ) |  |  | 141 |
|  |  | 15,011 |  |  |  | (7,326 | ) |  |  | 1,434 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration